Seong-Jang Kim1, Samuel Chang. 1. From the *Department of Nuclear Medicine and †Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea; and ‡Department of Radiology, University of Colorado School of Medicine, Aurora, CO.
Abstract
UNLABELLED: : The goal of the present study was to determine whether volumetric parameters such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) measured by sequential F-FDG PET/CT imaging could be used as prognostic factors in patients with locally advanced rectal cancer (LARC) who received preoperative concurrent chemoradiotherapy. METHODS: A total 64 patients with LARC patients were included in the current study. All patients were evaluated by F-FDG PET/CT before and after 45 Gy of radiotherapy with concurrent oral capecitabine chemotherapy. Initial, second, and the percent changes ([INCREMENT], %) of semiquantitative and volumetric parameters were used to calculate recurrence-free survival (RFS) and overall survival (OS). The cutoff values of semiquantitative and volumetric parameters were determined by receiver operating characteristic curve analysis. The prognostic significance was assessed using univariate and multivariate Cox proportional hazard regression analysis. RESULTS: For RFS, American Joint Committee on Cancer (AJCC) stage (χ = 10.7, P = 0.002), surgical margin (+) (χ = 3.39, P = 0.037), lymphatic invasion (+) (χ = 6.8, P = 0.0078), RECIST (Response Evaluation Criteria in Solid Tumors) (χ = 46.3, P < 0.0001), SUVmax1 (χ = 10.1, P = 0.025), ΔSUVmax (χ = 20.4, P < 0.0001), ΔSUVmean (χ = 28.8, P < 0.0001), MTV1 (χ = 24.1, P < 0.0001), ΔMTV (χ = 27.4, P < 0.0001), TLG1 (χ = 21.9, P < 0.0001), TLG2 (χ = 23.3, P < 0.0001), and ΔTLG (χ = 55.6, P < 0.0001) are associated prognostic factors. For OS, AJCC stage (χ = 6.0, P = 0.021), surgical margin (+) (χ = 3.2, P = 0.042), lymphatic invasion (+) (χ = 3.8, P = 0.048), RECIST (χ = 10.4, P = 0.0015), ΔSUVmax (χ = 6.0, P = 0.013), ΔSUVmean (χ = 10.5, P = 0.0009), MTV1 (χ = 14.5, P = 0.0008), ΔMTV (χ = 14.7, P = 0.0002), TLG1 (χ = 15.8, P = 0.0002), TLG2 (χ = 13.5, P = 0.0006), and ΔTLG (χ = 17.5, P < 0.0001) are potent predictors. Multivariate Cox proportional hazard regression analyses revealed that the initial MTV (MTV1) and ΔTLG were the potent predictors for RFS and OS. CONCLUSIONS: Our data suggest that MTV on initial pretreatment F-FDG PET/CT and ΔTLG of sequential F-FDG PET/CT after preoperative concurrent chemoradiotherapy in LARC patients could provide prognostic information.
UNLABELLED: : The goal of the present study was to determine whether volumetric parameters such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) measured by sequential F-FDG PET/CT imaging could be used as prognostic factors in patients with locally advanced rectal cancer (LARC) who received preoperative concurrent chemoradiotherapy. METHODS: A total 64 patients with LARCpatients were included in the current study. All patients were evaluated by F-FDG PET/CT before and after 45 Gy of radiotherapy with concurrent oral capecitabine chemotherapy. Initial, second, and the percent changes ([INCREMENT], %) of semiquantitative and volumetric parameters were used to calculate recurrence-free survival (RFS) and overall survival (OS). The cutoff values of semiquantitative and volumetric parameters were determined by receiver operating characteristic curve analysis. The prognostic significance was assessed using univariate and multivariate Cox proportional hazard regression analysis. RESULTS: For RFS, American Joint Committee on Cancer (AJCC) stage (χ = 10.7, P = 0.002), surgical margin (+) (χ = 3.39, P = 0.037), lymphatic invasion (+) (χ = 6.8, P = 0.0078), RECIST (Response Evaluation Criteria in Solid Tumors) (χ = 46.3, P < 0.0001), SUVmax1 (χ = 10.1, P = 0.025), ΔSUVmax (χ = 20.4, P < 0.0001), ΔSUVmean (χ = 28.8, P < 0.0001), MTV1 (χ = 24.1, P < 0.0001), ΔMTV (χ = 27.4, P < 0.0001), TLG1 (χ = 21.9, P < 0.0001), TLG2 (χ = 23.3, P < 0.0001), and ΔTLG (χ = 55.6, P < 0.0001) are associated prognostic factors. For OS, AJCC stage (χ = 6.0, P = 0.021), surgical margin (+) (χ = 3.2, P = 0.042), lymphatic invasion (+) (χ = 3.8, P = 0.048), RECIST (χ = 10.4, P = 0.0015), ΔSUVmax (χ = 6.0, P = 0.013), ΔSUVmean (χ = 10.5, P = 0.0009), MTV1 (χ = 14.5, P = 0.0008), ΔMTV (χ = 14.7, P = 0.0002), TLG1 (χ = 15.8, P = 0.0002), TLG2 (χ = 13.5, P = 0.0006), and ΔTLG (χ = 17.5, P < 0.0001) are potent predictors. Multivariate Cox proportional hazard regression analyses revealed that the initial MTV (MTV1) and ΔTLG were the potent predictors for RFS and OS. CONCLUSIONS: Our data suggest that MTV on initial pretreatment F-FDG PET/CT and ΔTLG of sequential F-FDG PET/CT after preoperative concurrent chemoradiotherapy in LARCpatients could provide prognostic information.
Authors: Pierre Lovinfosse; Marc Polus; Daniel Van Daele; Philippe Martinive; Frédéric Daenen; Mathieu Hatt; Dimitris Visvikis; Benjamin Koopmansch; Frédéric Lambert; Carla Coimbra; Laurence Seidel; Adelin Albert; Philippe Delvenne; Roland Hustinx Journal: Eur J Nucl Med Mol Imaging Date: 2017-10-18 Impact factor: 9.236
Authors: Shih-Hsin Chen; Kenneth Miles; Stuart A Taylor; Balaji Ganeshan; Manuel Rodriquez; Francesco Fraioli; Simon Wan; Asim Afaq; Robert Shortman; Darren Walls; Luke Hoy; Raymond Endozo; Aman Bhargava; Matthew Hanson; Joseph Huang; Sherif Raouf; Daren Francis; Shahab Siddiqi; Tan Arulampalam; Bruce Sizer; Michael Machesney; Nicholas Reay-Jones; Sanjay Dindyal; Tony Ng; Ashley M Groves Journal: Eur J Nucl Med Mol Imaging Date: 2021-04-10 Impact factor: 9.236